Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response
Ovarian Cancer, Fallopian Tube Neoplasms, Peritoneal Neoplasms
About this trial
This is an interventional prevention trial for Ovarian Cancer focused on measuring Ovarian Cancer, ACA 125, 6 or 9 vaccinations, immune response, Fallopian tube cancer, Peritoneal cancer
Eligibility Criteria
Inclusion Criteria: Patients with epithelial carcinoma arising in the ovary, fallopian tube or peritoneum, stages I-IV. These patients must have received initial surgery and chemotherapy with at least one platinum based chemotherapy regimen. Patients must have relapsed and now have completed chemotherapy for recurrent disease within the last 6 weeks. Eligible patients may have asymptomatic residual measurable disease on CT scan, and/or may have an elevated CA-125, or may be in complete clinical remission. Patients must have adequate hematologic, renal and hepatic functions. Exclusion Criteria: Patients with any other active malignancy concomitantly Patients within 3 weeks of prior cytotoxic or investigational chemotherapy Patients within 4 weeks of prior radiotherapy Patients within 6 weeks of prior immunotherapy Patients who have received any prior anti-cancer vaccine
Sites / Locations
- Clinic for Gynecology and Gyn. Oncology, Humboldt University
- University Clinic Carl Gustav Carus, Gynecological hospital
- Gynecologic Hospital
- University Gynecologic Hospital
- University Gynecologic Hospital
- Gynecologic Clinic of the Ernst-Moritz-Arndt-University
- University Clinic Schleswig-Holstein, Campus Kiel, Clinic for gynecology and obstetrics
- Otto-von-Guericke University, University Gynecological Hospital
- Clinic of the Philipps University Marburg, Clinic for gynecology, gyn. endocrinology and oncology
- University Gynecological Hospital
- Clinic for Gnyecology and gyn. Oncology HSK